Huntington Study Group Announces Initiation of Phase III Clinical Study of Valbenazine for the Treatment of Chorea Associated with Huntington Disease. Rochester, NY, November 14, 2019 –(PR.com)– The Huntington Study Group (HSG), a world leader in...
VBI Vaccines (NASDAQ: VBIV) (“VBI”), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, and Brii Biosciences (“Brii Bio”), a clinical-stage company committed to serving patients’ needs and improving...
– Company Plans to Use Previously Announced Positive Zimura Clinical Trial as One of Two Pivotal Trials – – Zimura R&D Symposium for Investors/Analysts to be Held on November 20, 2019 – – Conference Call and Webcast Today, November...
HOUSTON, Nov. 12, 2019 /PRNewswire/ — Soliton, Inc., (SOLY) (“Soliton” or the “Company”), a medical device company with a novel and proprietary platform technology licensed from The University of Texas on behalf of the MD Anderson Cancer...
SAN DIEGO, Nov. 12, 2019 (GLOBE NEWSWIRE) — Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing novel drugs to address treatment resistance, today announced initiation of a Phase 1/2 clinical study of its lead drug candidate...
Across all women and all cycles evaluated, Ovaprene prevented essentially all sperm from entering the cervical canal, a surrogate marker for contraceptive effectiveness. Currently marketed contraceptives with similar results in their PCT clinical studies subsequently...
Email
Text